Robert Iannone, executive vice president of research and development and chief medical officer of Jazz Pharmaceuticals, discusses the company’s neuroscience pipeline, its growing family of commercial products, and how its preparing to maintain its leadership in the treatment of the rare sleep disorder narcolepsy as new competitors move toward market.